34 completed, 8 terminated, 6 recruiting, 4 active not recruiting. 19 Phase 2, 18 Phase 3, 12 Phase 1, 4 Phase 4, 1 Not applicable.
Follow GLPG0634: new trials by email Literature Review of GLPG0634 trials Research Report on GLPG0634
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Tolerability, Pharmacokinetics, and Efficacy of Filgotinib for the Treatment of Polyarticular-course Juvenile Idiopathic Arthritis in Children and Adolescents Filgotinib - Polyarticular Course Juvenile Idiopathic Arthritis | Phase 3 | Recruiting | Alfasigma S.p.A. | 65 | 2026-05-21 | 2026-06-12 |
| OLE Study With Filgotinib in JIA Filgotinib - Juvenile Idiopathic Arthritis (JIA) | Phase 3 | Recruiting | Alfasigma S.p.A. | 80 | 2026-04-20 | 2026-08-10 |
| Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis Population Non-Interventional Study - Ulcerative Colitis | Active not recruiting | Pfizer | 4000 | 2026-04-01 | 2026-10-15 | |
| A Study Evaluating the Effects of Filgotinib in Children and Teenagers With Ulcerative Colitis Filgotinib - Ulcerative Colitis | Phase 3 | Recruiting | Alfasigma S.p.A. | 80 | 2025-09-29 | 2026-10-20 |
| JAK Inhibitor Dose TAPering Strategy Study Baricitinib (LY3009104) 4 mg, filgotinib 200mg/day, Tofacitinib 5 mg twice daily - Rheumatoid Arthritis (RA | Phase 4 | Recruiting | University Hospital, Toulouse | 308 | 2025-06-06 | 2026-08-07 |
| Filgotinib Effect on Proteomic Profile and Micro-RNA Expression in Patients With Active Rheumatoid Arthritis (RA) Filgotinib, Adalimumab - Rheumatoid Arthritis | Phase 4 | Unknown | Universita di Verona | 30 | 2024-07-15 | 2024-08-01 |
| Study to Measure Filgotinib in the Blood of Children and Teenagers With Arthritis Taking Filgotinib (SCALESIA) Filgotinib - Juvenile Idiopathic Arthritis | Phase 1 | Terminated | Alfasigma S.p.A. | 9 | 2024-05-13 | 2026-07-15 |
| Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases Filgotinib - Behcet's Disease, Idiopathic Inflammatory Myopathies | Phase 2 | Recruiting | UMC Utrecht | 60 | 2024-03-12 | 2026-05-12 |
| Relative Bioavailability and Effect of Food Study With an Oral Mini-tablet Formulation of Filgotinib in Healthy Subjects Filgotinib - Bioavailability | Phase 1 | Completed | Lakefront Biotherapeutics NV | 12 | 2023-09-22 | 2023-11-29 |
| Prospective Observational Study of Effectiveness and Safety of Filgotinib in Participants With Ulcerative Colitis (UC) Filgotinib - Ulcerative Colitis | Active not recruiting | Alfasigma S.p.A. | 509 | 2023-06-12 | 2025-12-24 | |
| A Study Evaluating the Effect of Filgotinib in Participants With Active Axial Spondyloarthritis Filgotinib, Placebo - Axial Spondyloarthritis | Phase 3 | Active not recruiting | Alfasigma S.p.A. | 495 | 2023-04-05 | 2025-12-04 |
| Januse Kinase Inhibition With Filgotinib to Silence Autoreactive B Cells in Rheumatoid Arthritis Filgotinib, Adalimumab - Rheumatoid Arthritis | Phase 4 | Unknown | Leiden University Medical Center | 40 | 2022-10-01 | 2022-08-16 |
| A Study Evaluating the Effect of Filgotinib Dose De-escalation in Participants With Ulcerative Colitis (UC) in Remission Filgotinib, Placebo - Ulcerative Colitis | Phase 3 | Terminated | Lakefront Biotherapeutics NV | 22 | 2022-07-26 | 2024-10-04 |
| Prospective Observational Study of Filgotinib in Participants With Rheumatoid Arthritis in France Filgotinib - Rheumatoid Arthritis | Completed | Alfasigma S.p.A. | 155 | 2022-05-03 | 2026-05-22 | |
| Screening for Flare After b/tsDMARD Discontinuation in Rheumatoid Arthritis Discontinuation of biological/targeted synthetic disease modifying anti-rheumatic drug (b/tsDMARD) - Rheumatoid Arthritis | Not applicable | Unknown | Medical University of Vienna | 85 | 2022-03-01 | 2021-11-15 |
| Better After CHoosing. Randomly Allocated or Patient Preference Based Treatment With Filgotinib or TNFi in RA (BACH) Filgotinib, Anti-Tumor Necrosis Factor Alpha Drug (Product), 50 patients will have a Free Choice between Filgotinib and anti TNF - Rheumatoid Arthritis | Phase 4 | Recruiting | R.Bos | 100 | 2021-05-12 | 2025-08-08 |
| Prospective Observational Study of Filgotinib in Subjects With Rheumatoid Arthritis Filgotinib - Rheumatoid Arthritis | Active not recruiting | Alfasigma S.p.A. | 1304 | 2021-05-11 | 2025-09-15 | |
| Efficacy and Safety of Selective JAK 1 Inhibitor Filgotinib in Active Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate filgotinib 200mg/day, subcutaneous tocilizumab 162mg/biweekly - Rheumatoid Arthritis, JAK Inhibitor | Phase 3 | Unknown | Atsushi Kawakami | 400 | 2021-03-03 | 2021-11-01 |
| Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Ankylosing Spondylitis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drug Therapy Filgotinib, Placebo to Match Filgotinib - Ankylosing Spondylitis | Phase 3 | Withdrawn | Gilead Sciences | 2020-12-01 | 2021-01-11 | |
| Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Ankylosing Spondylitis Who Have an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drug Therapy Filgotinib, Placebo to Match Filgotinib - Ankylosing Spondylitis | Phase 3 | Withdrawn | Gilead Sciences | 2020-12-01 | 2021-01-11 |
Showing 20 of 58. Sign in to see all of them.
Arthritis, Rheumatoid (21) · Colitis, Ulcerative (6) · Arthritis, Psoriatic (5) · Spondylitis, Ankylosing (4) · Arthritis, Juvenile (3) · Crohn Disease (3) · Axial Spondyloarthritis (1) · Behcet Syndrome (1) · Immunoglobulin G4-Related Disease (1) · Inflammatory Bowel Diseases (1) · Lupus Erythematosus, Cutaneous (1) · Myositis (1) · Renal Insufficiency (1) · Sjogren's Syndrome (1)
Lakefront Biotherapeutics NV (23) · Gilead Sciences (17) · Alfasigma S.p.A. (10) · Atsushi Kawakami (1) · Leiden University Medical Center (1) · Medical University of Vienna (1) · Pfizer (1) · R.Bos (1) · UMC Utrecht (1) · Universita di Verona (1) · University Hospital, Toulouse (1)
Belgium (27) · Germany (26) · Poland (26) · Spain (26) · United Kingdom (25) · United States (25) · Czechia (21) · France (20) · Hungary (20) · Ukraine (18) · Bulgaria (17) · Italy (16) · Australia (15) · Canada (14) · New Zealand (14)
Pille Harrison, MD (4) · Pille Harrison, MD, DPhil, MRCP (UK) (2) · Atsushi Kawakami, MD, PhD (1) · Catherine Vincent (1) · Eva Vets, MD (1) · Jaap M van Laar, Prof. dr. (1) · Lien Gheyle, MD (1) · Magdalena Petkova, MD (1)
PMID 36205910, PMID 37747626, PMID 25681059, PMID 34980223, PMID 38057656, PMID 38985247, PMID 28622463, PMID 31912462, PMID 35614292, PMID 36327094, PMID 37137672, PMID 37540206, PMID 37718932, PMID 42536126, PMID 27988142, PMID 27993828, PMID 27993829, PMID 30360969, PMID 30360970, PMID 31334793, PMID 31624837, PMID 33177349, PMID 33274687, PMID 33380521, PMID 33452004, PMID 33504485, PMID 33526618, PMID 34090625, PMID 34352069, PMID 34385364, PMID 34498056, PMID 34647992, PMID 35377447, PMID 35762272, PMID 36006011, PMID 36756874, PMID 36869356, PMID 36928705, PMID 36946138, PMID 37172783, PMID 37490202, PMID 37945284, PMID 38019901, PMID 38366672, PMID 39023880, PMID 39086130, PMID 39331638, PMID 39452892, PMID 39506562, PMID 39592547
2016 (12), 2017 (4), 2019 (4), 2023 (2), 2018 (1), 2025 (1)